Drug Trial Radar · NCT00000692
Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex
Last checked: Nov 19, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- G D SearleIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 1
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the following about the use of SC-48334 in patients with AIDS and advanced AIDS related complex (ARC): 1\. The largest maximum tolerated dose (MTD); 2. Effectiveness against HIV; 3. Pharmacokinetics - how fast SC-48334 reaches the bloodstream, what concentration is reached, and how long it remains in the patient's blood. SC-48334 is a chemical that prevents the biochemical actions of certain enzymes in the body, and recent studies have shown that it may also prevent the activity of HIV. The study will attempt to show whether SC-48334 can safely and effectively break the cycle of HIV infection in AIDS and advanced ARC by progressively eliminating HIV.
Conditions
- HIV Infections
Interventions
ButyldeoxynojirimycinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Univ of California / San Diego Treatment Ctr
San Diego, California
Stanford Univ School of Medicine
Stanford, California
Univ of Miami School of Medicine
Miami, Florida
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois
Harvard (Massachusetts Gen Hosp)
Boston, Massachusetts
Julio Arroyo
West Columbia, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.